Carboplatin: An organoplatinum compound that possesses antineoplastic activity.Paclitaxel: A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Platinum: Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".Lung Neoplasms: Tumors or cancer of the LUNG.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Ifosfamide: Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.Thrombocytopenia: A subnormal level of BLOOD PLATELETS.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Organoplatinum Compounds: Organic compounds which contain platinum as an integral part of the molecule.Area Under Curve: A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Retinal Neoplasms: Tumors or cancer of the RETINA.Fallopian Tube Neoplasms: Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Maximum Tolerated Dose: The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.LeukopeniaRetinoblastoma: A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104)Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.DeoxycytidineDose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Hematologic Diseases: Disorders of the blood and blood forming tissues.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.Seminoma: A radiosensitive, malignant neoplasm of the testis, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. There are three variants: classical (typical), the most common type; anaplastic; and spermatocytic. The classical seminoma is composed of fairly well differentiated sheets or cords of uniform polygonal or round cells (seminoma cells), each cell having abundant clear cytoplasm, distinct cell membranes, a centrally placed round nucleus, and one or more nucleoli. In the female, a grossly and histologically identical neoplasm, known as dysgerminoma, occurs. (Dorland, 27th ed)Drug Evaluation: Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.Taxoids: A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.Isocoumarins: Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.Drug Hypersensitivity: Immunologically mediated adverse reactions to medicinal substances used legally or illegally.Germinoma: A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Vinblastine: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)GuanineAntineoplastic Agents, Phytogenic: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.Glutamates: Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Neoplasms, Unknown Primary: Metastases in which the tissue of origin is unknown.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Feasibility Studies: Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Platinum Compounds: Inorganic compounds which contain platinum as the central atom.Alopecia: Absence of hair from areas where it is normally present.Folic Acid Transporters: Proteins involved in the transport of FOLIC ACID and folate derivatives across the CELLULAR MEMBRANE.Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).Triethylenephosphoramide: An insect chemosterilant and an antineoplastic agent.Urologic Neoplasms: Tumors or cancer of the URINARY TRACT in either the male or the female.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Hearing Loss, High-Frequency: Hearing loss in frequencies above 1000 hertz.Bone Marrow DiseasesBrain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Hyperthermia, Induced: Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. (1/1928)

Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bax (Chresta et al., 1996). To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Bcl-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was a reciprocal downregulation of the endogenously expressed Bcl-X(L) in the Bcl-2 overexpressing clones. Downregulation of Bcl-X(L) to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Bcl-2 and Bcl-X(L) have different abilities to protect against chemotherapy-induced apoptosis in testicular germ cell tumours. In contrast to findings in some tumour cell types, Bcl-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.  (+info)

A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. (2/1928)

Multinuclear platinum compounds have been designed to circumvent the cellular resistance to conventional platinum-based drugs. In an attempt to examine the cellular basis of the preclinical antitumor efficacy of a novel multinuclear platinum compound (BBR 3464) in the treatment of cisplatin-resistant tumors, we have performed a comparative study of cisplatin and BBR 3464 in a human osteosarcoma cell line (U2-OS) and in an in vitro selected cisplatin-resistant subline (U2-OS/Pt). A marked increase of cytotoxic potency of BBR 3464 in comparison with cisplatin in U2-OS cells and a complete lack of cross-resistance in U2-OS/Pt cells were found. A detailed analysis of the cisplatin-resistant phenotype indicated that it was associated with reduced cisplatin accumulation, reduced interstrand cross-link (ICL) formation and DNA platination, microsatellite instability, and reduced expression of the DNA mismatch repair protein PMS2. Despite BBR 3464 charge and molecular size, in U2-OS and U2-OS/Pt cells, BBR 3464 accumulation and DNA-bound platinum were much higher than those observed for cisplatin. In contrast, the frequency of ICLs after exposure to BBR 3464 was very low. The time course of ICL formation after drug removal revealed a low persistence of these types of DNA lesions induced by BBR 3464, in contrast to an increase of DNA lesions induced by cisplatin, suggesting that components of the DNA repair pathway handle the two types of DNA lesions differently. The cellular response of HCT116 mismatch repair-deficient cells was consistent with a lack of influence of mismatch repair status on BBR 3464 cytotoxicity. Because BBR 3464 produces high levels of lesions different from ICLs, likely including intra-strand cross-links and monoadducts, the ability of the triplatinum complex to overcome cisplatin resistance appears to be related to a different mechanism of DNA interaction (formation of different types of drug-induced DNA lesions) as compared with conventional mononuclear complexes rather than the ability to overcome specific cellular alterations.  (+info)

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. (3/1928)

PURPOSE: Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high response rates have been reported when it is administered in combination with cisplatin. The aim of the present study was to evaluate the combination of gemcitabine and carboplatin in a phase I-II study. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB-IV non-small-cell lung cancer received carboplatin at area under the concentration-time curve (AUC) 5 mg/mL/min and gemcitabine at an initial dose of 800 mg/m2, subsequently escalated by 100 mg/m2 per step. Gemcitabine was administered on days 1 and 8 and carboplatin on day 8 of the 28-day cycle. Dose escalation proceeded up to dose-limiting toxicity (DLT), which was defined as grade 4 neutropenia or thrombocytopenia or grade 3 nonhematologic toxicity. RESULTS: Neutropenia was DLT, inasmuch as it occurred in three of five patients receiving gemcitabine 1,200 mg/m2. Nonhematologic toxicities were mild. Gemcitabine 1,100 mg/m2 plus carboplatin AUC 5 was recommended for phase II studies. An objective response was observed in 13 (50%) of 26 patients, including four complete responses (15%) and nine partial responses (35%). Median duration of response was 13 months (range, 3 to 23 months). Median overall survival was 16 months (range, 3 to 26 months). CONCLUSION: The combination of gemcitabine and carboplatin is well tolerated and active. Neutropenia was DLT. The observed activity matches that observable in cisplatin-gemcitabine studies, whereas duration of response and survival are even higher. A phase II trial is under way.  (+info)

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. (4/1928)

PURPOSE: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE). PATIENTS AND METHODS: We performed a phase II study with PC in SCLC patients who relapsed within 3 months after first-line treatment with CDE. Paclitaxel administration (175 mg/m2 by a 3-hour intravenous infusion) was followed by a 30-minute infusion of carboplatin (area under the curve 7; Chatelut formula) once every 3 weeks for five cycles. Dexamethasone, clemastine, and ranitidine were standard premedication before every cycle. RESULTS: Included were 35 patients (median age, 59 years; 16 with limited disease and 19 with extensive disease; Eastern Cooperative Oncology Group performance status of < or = 1; median time off treatment 6 weeks) who were previously treated with CDE (n = 33), oral etoposide (n = 2), and reinduction CDE (n = 15); only one patient had received three CDE treatments of five cycles. The CDE regimen was followed by local thoracic radiotherapy in seven patients. Hematologic toxicity of grade 3 or 4, for leukopenia was 27% and 6%, for thrombocytopenia 21% and 13%, and for anemia 17% and 0%, respectively, for a total of 132 cycles. Two patients had neutropenic fever; no toxic death occurred. Nonhematologic toxicity was paresthesia CTC grade 3, diarrhea grade 4, and myalgia grade 3 in one patient each. Reversible paresthesia (CTC grade 1 and 2) in toes and fingers was reported in 69% of patients. Thirty-four patients were assessable for response: complete response in two patients, partial response in 23 patients, stable disease in eight patients, and progressive disease in one patient (response rate, 73.5%; 95% confidence interval, 59% to 88%). One patient was found to have atypical carcinoid at pathologic review and was excluded. Median time to progression was 21 weeks (range, 3 to 40 weeks). Median survival was 31 weeks (range, 6 to 112 weeks). One-year survival was 9%. CONCLUSION: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.  (+info)

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. (5/1928)

PURPOSE: To determine the maximum-tolerated dose of paclitaxel with carboplatin with and without filgrastim support in patients with metastatic non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of paclitaxel and carboplatin and correlate these with the pharmacodynamic effects. PATIENTS AND METHODS: Thirty-six chemotherapy-naive patients with metastatic NSCLC were entered into this phase I dose-escalation and pharmacokinetic study. Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute. A measured 24-hour urinary creatinine clearance was substituted for the glomerular filtration rate. Once the maximum-tolerated AUC (MTAUC) of carboplatin was reached, the paclitaxel dose was escalated to 175, 200, and 225 mg/m2. When the paclitaxel dose escalation began, the AUC of carboplatin was reduced to one level below the MTAUC. RESULTS: Myelosuppression was the major dose-limiting toxicity. Thrombocytopenia was observed at a carboplatin AUC of 11 mg/mL x minute after course 2 and thereafter. End-of-infusion plasma paclitaxel concentrations and median duration of time above 0.05 microM were similar in course 1 versus course 2 at the 135 and 175 mg/m2 dose levels. The neutropenia experienced by patients was consistent with that observed in patients who had received paclitaxel alone. Measured carboplatin AUCs were approximately 12% (20% v 3% with course 1 v course 2, respectively) below the desired target, with a standard deviation of 34% at all dose levels. A sigmoid-maximum effect model describing the relationship between relative thrombocytopenia and measured free platinum exposure indicated that patients who received the combination of carboplatin with paclitaxel experienced less severe thrombocytopenia than would be expected from carboplatin alone. Of the 36 patients entered onto the study, one experienced a complete response and 17 had partial responses, for an overall response rate of 50%. The recommended doses of paclitaxel (24-hour infusion) and carboplatin for future phase II studies of this combination are (1) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute with filgrastim support. CONCLUSION: The regimen of paclitaxel and carboplatin is well-tolerated and has promising activity in the treatment of NSCLC. There is no pharmacokinetic interaction between paclitaxel and carboplatin, but there is a pharmacodynamic, platelet-sparing effect on this dose-limiting toxicity of carboplatin.  (+info)

Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. (6/1928)

PURPOSE: An earlier phase II trial of paclitaxel in patients with metastatic nasopharyngeal carcinoma (NPC) demonstrated a response rate of 22%. Hence we proceeded to study the combination of paclitaxel and carboplatin in these patients. PATIENTS AND METHODS: The 21-day regimen was as follows: i.v. paclitaxel 175 mg/m2 over three hours preceded by standard premedications, followed by i.v. carboplatin dosed at AUC of six infused over one hour. Only chemotherapy-naive patients with histological diagnoses of undifferentiated carcinoma of the nasopharynx, systemic metastases and radiologically measurable lesions were eligible. RESULTS: Thirty-two patients were accrued to this study. Twenty patients (62%) had at least two sites of metastasis. The main grade 3-4 toxicity was neutropenia (31%). Nine patients (28%) developed neutropenic sepsis, which caused the demise of one of them. Twenty-four patients (75%) responded to treatment, with one (3%) attaining a complete response. The median time to progression of disease was seven months and the median survival was 12 months. At one year, 52% of the patients were alive. CONCLUSIONS: The combination of paclitaxel and carboplatin is an active regimen in NPC. Its convenience of administration and good tolerability make it an attractive alternative regimen to consider for patients with metastatic disease.  (+info)

Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Societe Francaise d'Oncologie Pediatrique. (7/1928)

Conventional therapy for intracranial germinomas is craniospinal irradiation. In 1990, the Societe Francaise d'Oncologie Pediatrique initiated a study combining chemotherapy (alternating courses of etoposide-carboplatin and etoposide-ifosfamide for a recommended total of four courses) with 40 Gy local irradiation for patients with localized germinomas. Metastatic patients were allocated to receive low-dose craniospinal radiotherapy. Fifty-seven patients were enrolled between 1990 and 1996. Forty-seven had biopsy-proven germinoma. Biopsy was not performed in ten patients (four had diagnostic tumour markers and in six the neurosurgeon felt biopsy was contraindicated). Fifty-one patients had localized disease, and six leptomeningeal dissemination. Seven patients had bifocal tumour. All but one patient received at least four courses of chemotherapy. Toxicity was mainly haematological. Patients with diabetus insipidus (n = 25) commonly developed electrolyte disturbances during chemotherapy. No patient developed tumour progression during chemotherapy. Fifty patients received local radiotherapy with a median dose of 40 Gy to the initial tumour volume. Six metastatic patients, and one patient with localized disease who stopped chemotherapy due to severe toxicity, received craniospinal radiotherapy. The median follow-up for the group was 42 months. Four patients relapsed 9, 10, 38 and 57 months after diagnosis. Three achieved second complete remission following salvage treatment with chemotherapy alone or chemo-radiotherapy. The estimated 3-year survival probability is 98% (CI: 86.6-99.7%) and the estimated 3-year event-free survival is 96.4% (CI: 86.2-99.1%). This study shows that excellent survival rates can be achieved by combining chemotherapy and local radiotherapy in patients with non-metastatic intracranial germinomas.  (+info)

1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. (8/1928)

The majority of men who die from prostate cancer (PC) have hormone-refractory disease. To date, chemotherapeutic agents have had little or no impact on the survival of such patients. To explore a new approach for the treatment of hormone-refractory PC, we examined the combination effects of cis- or carboplatin with vitamin D. 1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3) and its synthetic analogue, Ro 25-6760, have an antiproliferative effect on some prostate cancer cell lines. Consequently, the growth-inhibitory effects of the drugs were measured, both singularly and in combination with cis- or carboplatin, on PC cells. Our results show that although each of the drugs alone displayed antiproliferative activity, the growth inhibition of PC cells was further enhanced by the combination of 1alpha,25(OH)2D3 or Ro 25-6760 and either platinum agent. The greatest enhancement of inhibition occurred using smaller concentrations of the platinum compound in combination with higher concentrations of 1alpha,25(OH)2D3. Isobologram analysis revealed that 1alpha,25(OH)2D3 and platinum acted in a synergistic manner to inhibit the growth of PC cells. Our findings suggest that there is potential clinical value in combining 1alpha,25(OH)2D3 with platinum compounds for the treatment of advanced-stage human PC.  (+info)

A comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly gemcitabine in elder patients (, 75) with previously untreated advanced non-small cell lung cancer. Primary objective is to determine the objective response rate (CR+PR by RECIST criteria) for biweekly gemcitabine and carboplatin combination chemotherapy versus weekly single gemcitabine as first-line therapy in elder advanced non-small lung cancer patients (, 76 years) who have received no prior treatment for non-small lung cancer. As secondary objectives, adverse event profile, tolerability of biweekly gemcitabine and carboplatin combination chemotherapy, progression-free survival and overall survival will be evaluated in both patients with biweekly gemcitabine and carboplatin combination chemotherapy and weekly single gemcitabine.. The study hypothesis is that biweekly combination chemotherapy of gemcitabine plus carboplatin may improve the efficacy. ...
OBJECTIVES: To evaluate the efficacy of combination of navitoclax, carboplatin and paclitaxel in ovarian cancer.. METHODS: 8 ovarian cancer cell lines were treated with either doublet or triplet combinations of navitoclax, carboplatin and paclitaxel. Interactions were assessed by determining a combination index or measuring caspase activity. The effect of the combinations was also evaluated by measuring the inhibition of cells grown as spheroids.. RESULTS: Navitoclax exhibited modest (IC(50)=3-8 μM) single agent potency. Antagonism between carboplatin and paclitaxel was evident in Ovcar-4, Ovcar-8 and Skov-3 cells. Drug combinations including navitoclax with carboplatin and/or paclitaxel showed significantly less antagonism, or even synergy, in several cell lines than carboplatin/paclitaxel alone. Navitoclax enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells. Combinations of navitoclax, carboplatin and paclitaxel showed more than additive activity ...
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous NSCLC) bevacizumab (B). Anticipated time on study treatment is until disease progression or intolerable toxicity occurs. Participants in placebo arms with disease progression may cross over to open-label active pictilisib ...
Looking for online definition of Paclitaxel/Carboplatin or what Paclitaxel/Carboplatin stands for? Paclitaxel/Carboplatin is listed in the Worlds largest and most authoritative dictionary database of abbreviations and acronyms
An analysis of the GeparSixto trial in triple-negative breast cancer showed that adding carboplatin to neoadjuvant therapy improved pathologic complete response rate in patients without BRCA1/2 mutation and that response rates were higher overall in those with mutations, without additive effects observed for carboplatin. The analysis was reported by Hahnen et al in JAMA Oncology. GeparSixto showed the addition of neoadjuvant carboplatin to anthracycline, taxane, and bevacizumab (Avastin) increased pathologic complete response rates among all patients.. Study Details The current analysis included 291 patients, of whom 146 received carboplatin. Pathogenic BRCA1 and BRCA2 germline mutations were present in 50 patients (17.2%), including 26 patients who received carboplatin and 24 patients who did not.. Pathologic Complete Response Rate. The pathologic complete response rate was 56.8% in the carboplatin group vs 41.4% in the group that did not receive carboplatin (odds ratio [OR] = 1.87, P = .009). ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC ...
To report the results of combined chemoradiation (CCRT) with cisplatin versus carboplatin in locally advanced cervical carcinoma. From 2009 to 2013, 255 patients with stage IIB-IVA cervical carcinoma, according to FIGO staging were prospectively assigned to be treated with pelvic radiotherapy followed by brachytherapy given concurrently with cisplatin or carboplatin in the treatment of locally advanced cervical cancer. Treatment outcomes and toxicitiy were evaluated. Two-hundred and thirteen patients could be evaluated. At a median follow-up time of 43 months (6-69 months), the 3-year local control, disease-free survival, metastasis-free survival and overall survival rates were 93, 80.8, 85.0 and 87.3 %, respectively. No statistical difference in terms of local control, disease-free survival, metastasis-free survival and overall survival rates between cisplatin and carboplatin treatments was observed in this study. Eighty-six percents of the patients in the carboplatin group could receive more than 4
The combination of carboplatin-paclitaxel is a global standard following recent consensus recommendations [20, 4]. Although this treatment is highly effective, most patients recur. The majority are platinum-sensitive at first relapse, thus, candidates for re-treatment with platinum. Indeed, these patients will be generally re-treated with a platinum-taxane combination, especially in the light of recent trials showing advantage over platinum monotherapy [9]. However, the cumulative neurotoxicity of both drugs, as well as the increased risk of neurotoxicity for patients in relapse and the further experience of alopecia, are essential considerations when selecting second-line therapy [21]. As treatment at relapse is rarely curative, toxicity, tolerance, ease of administration and QoL should be interrelated to efficacy and survival prolongation when novel platinum-based combinations are evaluated for patients with platinum-sensitive OC.. This study was originally designed in 1999, in an era when ...
Materials and methods The overall number of patients and carboplatin courses, sex, age, diagnosis and percentage overdose were extracted from the Farmis database on cytostatics management, from January 2011 to September 2013. Overdoses were designated: carboplatin dosing ,900 mg for a target AUC = 6; carboplatin dosing ,750 mg for a target AUC = 5; carboplatin dosing ,600 mg for a target AUC = 4. In the event of overdosing (Common Terminology Criteria for Adverse Events (CTCAE) criteria), blood tests were sought before the next round of treatment and the need to delay the chemotherapy treatment were evaluated.. ...
Patients and Methods Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m2 on days 1, 8, and 15 plus cisplatin 60 mg/m2 on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m2 plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events ...
Carboplatin, Carboplatin Suppliers Directory - Find variety Carboplatin Suppliers, Manufacturers, Companies from around the World at ,
Find out about the science and chemistry of Carboplatin (Paraplatin), see colourful images of Carboplatin and explore interactive 3D molecules of Carboplatin
Purpose: Patupilone is a microtubule-targeting chemotherapeutic agent with clinical activity in a broad range of taxane-sensitive/resistant tumor types. The present phase lb study examined the safety/tolerability and pharmacokinetics of patupilone in combination with carboplatin in patients with advanced solid tumors. Experimental Design: Patients with advanced cancer received patupilone via a 5- to 10-min i.v. infusion at doses of 3.6 to 6.0 mg/m(2) q3w, immediately followed by carboplatin area under the curve (AUC) 5 or 6 mg/mL/min. Results: Of the 37 patients enrolled, the majority previously received taxanes (81%) and/or platinum-containing drugs (97.3%). The maximum tolerated dose (MTD) of patupilone with carboplatin AUC 6 was 4.8 mg/m2; additional patients were enrolled to consolidate experience at this dose. Of the 22 patients who received the MTD, the most common nonhematologic adverse events were fatigue in six (27.3%) and diarrhea, nausea, vomiting, abdominal pain, and neuropathy in ...
nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial Cesare Gridelli,1 Tianlei Chen,2 Amy Ko,2 Mary E O’Brien,3 Teng Jin Ong,4 Mark A Socinski,5 Pieter E Postmus6 1Division of Medical Oncology, S. G. Moscati Hospital, Avellino, Italy; 2Biostatistics, Celgene Corporation, Summit, NJ, USA; 3Medical Oncology, Royal Marsden Hospital, London, UK; 4Medical Affairs, Celgene Corporation, Summit, NJ, USA; 5Lung Cancer & Esophageal Cancer, Florida Hospital Cancer Institute, Orlando, FL, USA; 6Pulmonary Diseases, Clatterbridge Cancer Center, Liverpool, UK Background: Limited data on elderly patients with squamous advanced non-small cell lung cancer (NSCLC) preclude optimal treatment. Here, we report the outcomes of a retrospective analysis of a subset of patients ≥70 years with squamous histology from the Phase III trial that evaluated nab-paclitaxel/carboplatin vs paclitaxel/carboplatin. Patients and methods
This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cancer (NSCLC). Eligible patients had Stage III or IV (oligometastatic) NSCLC. Patients received XRT to 63 Gy in standard fractionation. Patients received concurrent carboplatin (AUC = 6) during weeks 1 and 5 of XRT, and pemetrexed during weeks 1, 3, 5, and 7 of XRT. The starting dose level (level 1) of pemetrexed was 300 mg/m2. Following the finding of dose limiting toxicity (DLT) in dose level 1, an amended dose level (level 1A) continued pemetrexed at 300 mg/m2, but with involved field radiation instead of extended nodal irradiation. Consolidation consisted of carboplatin (AUC = 6) and pemetrexed (500 mg/m2) q3 weeks × 2 -3 cycles. Eighteen patients were enrolled. Fourteen patients are evaluable for toxicity analysis. Of the initial 6 patients treated on dose level 1, two experienced DLTs (one grade
article{7b211b82-b7cf-45eb-9b6c-526d9db736a8, abstract = {Chemotherapy resistance remains a major obstacle to successful treatment of ovarian cancer patients. Therefore, increased knowledge of underlying mechanisms and identification of predictive factors are of great importance. Standard treatment for ovarian carcinoma is surgery followed by platinum-based chemotherapy. In this study, we aimed to search for genes or genomic regions involved in platinum resistance in ovarian carcinoma. Array-based comparative genomic hybridization (CGH) was used to identify genetic alterations in 32 early-stage epithelial ovarian carcinomas homogeneously treated with single-agent carboplatin. The arrays contain 33,370 bacterial artificial chromosome (BAC) clones and form a contiguous and tiling coverage of the human genome with an average resolution of similar to 100 kb. We found certain genetic changes associated with carboplatin response. Gains in 1q25.1-q41 were significantly more frequent in ...
Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combinati
carboplatin 41575-94-4 MSDS report, carboplatin MSDS safety technical specifications search, carboplatin safety information specifications ect.
It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to check for unwanted effects. While you are being treated with carboplatin, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctors approval. Carboplatin may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine since there is a chance they could pass the polio virus on to you. Also, avoid persons who have taken oral polio vaccine within the last several months. Do not get close to them, and do not stay in the same room with them for very long. If you cannot take these precautions, you should consider wearing a protective face mask that covers the nose and mouth. Carboplatin can temporarily lower the number of white blood cells in your blood, increasing the chance of ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total
The combination of carboplatin plus paclitaxel was less toxic and trended toward better survival as compared with 5-fluorouracil and cisplatin.
Adding aprepitant to palonosetron and dexamethasone provided no improvement in carboplatin-induced emesis in non-small cell lung cancer (NSCLC).
AIM: To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial. PATIENTS AND METHODS: The international non-inferiority trial enrolled women with ROC that relapsed ,6 months following first- or second-line platinum- and paclitaxel-based therapies. Patients were randomised to CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) and stratified by treatment-free interval (TFI). In this analysis, patients with a TFI,24 months were analysed separately for progression free survival (PFS), the primary endpoint of CALYPSO, overall survival (OS) and safety. RESULTS: A total of 259 very platinum-sensitive patients were included (n=131, CD; n=128, CP). Median PFS was 12.0 months for the CD arm and 12.3 months for CP [HR=1.05 (95% CI, 0.79-1.40); P=0.73 for superiority] and median OS was 40.2 months for CD and 43.9 for CP [HR=1.18 (95% CI 0.85-1.63); P=0.33 for superiority]. Overall response ...
This paper investigates a longitudinal tumour response model to describe and predict the response of the primary lesion in non-small cell lung cancer (Figure 2, taken from here) to gemcitabine (with carboplatin) chemotherapy. A total of 202 tumour size measurements from 56 patients were used to establish the pharmacodynamic model for tumour response. Gemcitabine was infused at either a fixed dose rate of 750mg/m2 over 75 mins or 1000mg/m2 over 30 mins on days 1 and 8 every 3 week in stage IIIB or IV non-small cell lung cancer patients. Carboplatin dose was administered as a 1hour infusion just before gemcitabine on day 1 of every cycle to patients. The pharmacokinetic exposure variables are the Gemcitabine dose and the AUCs (concentration-time curve) corresponding to each dose given, over the entire duration of treatment. Serial measurements of the largest dimension of the primary tumour were done on radiological images using electronic calipers at baseline after cycles 2, 4 and 6 and bimonthly ...
This study will compare the efficacy and tolerability of paclitaxel + carboplatin versus gimeracil/oteracil/tegafur + carboplatin in patients with advanced
Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.: Th
A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment of ovarian cancer. Therefore the use of imaging biomarkers early after initiation of treatment to determine treatment sensitivity would be valuable in order to identify responders from non-responders. In this study we describe the non-invasive PET imaging of glucose uptake and cell proliferation using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3-deoxy-3-[(18)F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of human ovarian cancer treated with carboplatin and paclitaxel ...
A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment of ovarian cancer. Therefore the use of imaging biomarkers early after initiation of treatment to determine treatment sensitivity would be valuable in order to identify responders from non-responders. In this study we describe the non-invasive PET imaging of glucose uptake and cell proliferation using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3-deoxy-3-[(18)F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of human ovarian cancer treated with carboplatin and paclitaxel ...
This trial is investigating the efficacy, tolerability and quality-of-life effects of bevacizumab [Avastin] in combination with carboplatin or paclitaxel, in
The FDA requires all potential medication risks for CARBOPLATIN (injection, solution) be disclosed to consumers, no matter how rare. Here are the warnings and precautions for Carboplatin.
International Scholarly Research Notices is a peer-reviewed, Open Access journal covering a wide range of subjects in science, technology, and medicine. The journals Editorial Board as well as its Table of Contents are divided into 108 subject areas that are covered within the journals scope.
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in H
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel, work in different ways to stop tumor cells from dividing so the
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..
Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks ...
4029 Background: Cetuximab is an IgG1, chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor. Cetuximab improves survival when combined with radiation for patients with locally advanced head and neck cancer. We evaluated the safety and efficacy of the addition of cetuximab to concurrent chemoradiation for patients with esophageal and gastric cancer. METHODS Patients with adenocarcinoma or squamous cell cancer of the esophagus or stomach without distant organ metastases were eligible. Patients with locally advanced disease from mediastinal, celiac, portal and gastric lymphadenopathy were eligible. Surgical resection was not required. Clinical complete response was defined as no tumor on postreatment endoscopic biopsy. Patients received cetuximab, 400mg/m2 week #1 then 250 mg/m2/week for 5 weeks, paclitaxel, 50 mg/m2/week, and carboplatin, AUC =2 weekly for 6 weeks, with concurrent 50.4 Gy radiation. RESULTS Thirty-seven patients have been entered. The median
Longer Term Follow-Up Data with Mercks KEYTRUDA in Combination with Pemetrexed and Carboplatin in First-Line Nonsquamous Metastatic Non-Small C
An open-label, dose-finding study to evaluate the safety and pharmacokinetics of AMG 706 with Carboplatin/Paclitaxel, AMG 706 with Panitumumab and AMG 706 with Panitumumab and Carboplatin/Paclitaxel in the treatment of subjects with advanced non-small cell lung ...
Evidence for dose modifications is limited, and the recommendations made on eviQ are intended as a guide only. They are generally conservative with an emphasis on safety. Any dose modification should be based on clinical judgement, and the individual patients situation including but not limited to treatment intent (curative vs palliative), the antineoplastic regimen (single versus combination therapy versus chemotherapy versus immunotherapy), biology of the cancer (site, size, mutations, metastases), other treatment related side effects, additional co-morbidities, performance status and patient preferences. Suggested dose modifications are based on clinical trial findings, product information and reference committee consensus. Non-haematological gradings are based on Common Terminology Criteria for Adverse Events (CTCAE) unless otherwise specified. Renal and hepatic dose modifications have been standardised where possible. For more information see dosing considerations & disclaimer. ...
Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of
My husband is facing 2 HDC with Carboplatin for relapsed yolk sac after 14 years being clear. After 4TIPs AFP fell from 88000 to 650, mass in the liver shrank twice to 4 cm, lungs are clear, RPL nodes apart from cloud around IVC are normal size, cloud has shrunk from 8cm to 6cm, IVC seems to be less
Carboplatin - - - - Package - Contents - Shelf Life: Vial, plastic, 1 x 5 mL - 5 mL - 24 months from date of manufacture stored at or below 25°C - Vial, plastic, 1 x 15 mL - 15 mL - 24 months from date of manufacture stored at or below 25°C - Vial, plastic, 1 x 4
WHITE PHARMACEUTICALS - Exporter, Importer, Distributor, Supplier, Trading Company of Adcarb - Carboplatin 450 mg based in New Delhi, India
Im sorry to hear that you had a bad reaction to the taxol, but its my understanding that its not a rare thing to have because its a plant derivative; thats why its usually administered in a hospital setting for the first treatment, so if theres an adverse reaction, you can be given as aid as possible. My ob/gyn said that when she was an intern, the taxol was still being filtered in the drip line because it sometimes had plant matter in it!. I had ovarian 1C and uterine 1B cancers, and was diagnosed in Sept. 2002, followed by 6 taxol/carboplatin treatments. It was scary at first, and I was very leery of what they were putting into me. I have since learned that it is standard treatment, and doses are administered by doctors are the same at hospitals or other facilities. I remember calling and demanding to know what I was given the second time, because it didnt seem to exactly match what I was given at the first!. You didnt mention if you were given steroid pills to take the night and ...
For breast cancers not responsive to Herceptin, or HER2 negative, Kadcyla isnt much use. AbbVie has a Phase 2 candidate that looks like it can fill the gap. During the San Antonio Breast Cancer Symposium last December, AbbVie presented some encouraging data from a Phase 2 study including veliparib, or ABT-888. The I-SPY 2 trial employed an adaptive design to screen for compounds that will be superior to chemotherapy alone, for specific cancer signatures.. Based on the responses seen in 115 patients, AbbVies veliparib combined with carboplatin and chemotherapy showed a 90% probability of being superior to chemotherapy alone in triple-negative patients. It is possible that carboplatin alone, and not veliparib, was responsible, but I doubt it. Carboplatin has been available for over 20 years. It is very likely that Veliparib will enter Phase 3 trials.. Final thoughts ...
Pujade-Lauraine E, Wagner U, Aavall-Lundquist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse (ONLINE). J Clin Oncol 2010 ...
p,Purpose: The PARP inhibitor, talazoparib, may potentiate activity of chemotherapy in cells vulnerable to DNA damage. Experimental Design: This phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK), and efficacy of talazoparib and carboplatin. Pharmacokinetic-modeling explored associations between dosing and hematological toxicity. Results: 24 patients with solid tumors were enrolled in 4 cohorts at 0.75mg and 1mg daily talazoparib and weekly carboplatin (AUC 1 and 1.5, Q2W or Q3W). Dose-limiting toxicities included grade 3 fatigue and grade 4 thrombocytopenia; the maximum tolerated dose was not reached. Grade 3/4 toxicities included fatigue (13%), neutropenia (63%), thrombocytopenia (29%), and anemia (38%). Post-cycle 2 dose modifications were required in all patients. One complete and two partial responses occurred in germline BRCA1/2 (gBRCA1/2) patients. Four patients showed stable disease beyond four months, three of which had mutations in DNA repair pathways. ...
The purpose of this study is to determine the therapeutic efficacy and complications of systemic consolidation therapy with paclitaxel plus carboplatin following primary chemoradiation for locally advanced cervical cancer.
Background: The aim of the study is to demonstrate that intrapatient dose escalation of carboplatin would improve the outcome in ovarian cancer compared with flat dosing. Patient and method: Patients with untreated stage IC-IV ovarian cancer received six cycles of carboplatin under the curve 6 (AUC 6) 3 weekly either with no dose modification except for toxicity (Arm A) or with dose escalations in cycles 24 based on nadir neutrophil and platelet counts (Arm 9), The primary end-point was progression-free survival (PPS). Results: Nine hundred and sixty-four patients were recruited from 71 centers, Dose oscalation was achieved in 77% of patients who had 1 cycle, The median AUCs (cycle 24) received were 6,0 Won A) and 72 Grade 3/4 non-hematological toxicity was higher in Arm 9 (31% versus 22% P=0.001), The median PFS was 12,1 months in Arm A and 9 [hazard ratio (HR) 0.00; 95% confidence interval (CI) 0.85=1.15; P = 0.03]. The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, ...
Preclinical data has demonstrated the potential of the intraductal administration of chemotherapy for breast cancer prevention. Direct translation of this work has been stymied by the anatomical differences between rodents (one duct per teat) and women (5-9 ductal systems per breast). The objective of this Phase I study was to demonstrate the safety and feasibility of intraductal administration of chemotherapy drugs into multiple ducts within one breast in women awaiting mastectomy for treatment of invasive cancer. Thirty subjects were enrolled in this dose escalation study conducted at a single center in Beijing, China. Under local anesthetic, one of two chemotherapy drugs, carboplatin or pegylated liposomal doxorubicin (PLD), was administered into 5-8 ducts at 3 dose levels. Pharmacokinetic analysis demonstrated that carboplatin was rapidly absorbed into the bloodstream, while PLD, though more erratic, was absorbed after a delay. Pathological analysis showed marked effects on breast duct ...
Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab ...
Platinum resistance in ovarian cancer is associated with accumulation of epigenetic changes leading to transcriptional silencing of tumor suppressor and chemo-r...
This phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.. ...
Dear Members and Staff,. My sister, age 49, was diagnosed with NSCLC, stage IV, adenocarcinom, EGFR -mutation, exon 21(L858R), 4 years ago. She was on Tarceva for a little less than a year, followed by chemotherapy (carboplatin+ alimta). When she developed T790-mutation, she did very well on Tagrisso for over a year. However, this summer, her general well-being has declined and X-rays show tumour progression. A new biopsy of the main tumour has revealed that her tumour has transformed into squamous lung cancer. According to the mutational analysis, the tumour has the following markers: P40, CK7 positive and PD-L1-negative.. Her oncologist is now suggesting a second round of chemotherapy(carboplatin and gemzar). We would very much appreciate any suggestions regarding further treatment that my sister could have. Please note that we live in Europe/Sweden.. Would it be a good idea to add cetuximab to the chemotherapy, considering she has been diagnosed with squamous lung cancer? Are you aware of any ...
Hi, CathyK!. I have recurrent stage 2 endometrial cancer. After the hysterectomy I was clear of cancer for about 6 months and then my CA125 number started to rise. I was being checked every 3 months. My doctor ordered a ct scan and we found cancer in 3 lymph nodes in my abdomen. He gave me 6 sessions of chemo - Taxol and Carboplatin. A CA125 test was run every 3 weeks during the chemo. The Taxol and Carboplatin did the job - for a while. In 6 months my ca125 number started to rise again and another ct scan showed more cancer in lymph nodes further up my body. I then had 25 sessions of radiation and 4 chemo sessions with Doxol. The Ca125 number kept rising so we stopped the Doxol and I just got home from another ct scan. Your doctor may mean the specific type of cancer cell you have doesnt produce the cancer antigen 125 so the test would not give you an acurate prediction of cancer growth. I have estrogen positive cancer and this test does give us a good heads-up that the cancer is ...
If you or someone close to you has been diagnosed with cancer, youre not alone. Find out what to expect, get information, practical advice and support, hear from experts and read about other peoples experiences.
If you or someone close to you has been diagnosed with cancer, youre not alone. Find out what to expect, get information, practical advice and support, hear from experts and read about other peoples experiences.
Our purpose was to determine the maximum tolerated dose of, and the minimum interval between treatments with, multiple cycles of carboplatin (CBDCA) rescued with peripheral blood progenitors and filgrastim. Eligible patients had advanced cancers without prior chemotherapy or radiotherapy. The study design involved a sequential cross-over in which patients initially received two or three courses of cyclophosphamide (CPA) at a dose of 3.0 g/m2, supported by filgrastin. Multiple leukaphereses were then performed during the rebound phase of hematological recovery following each CPA-induced nadir to harvest peripheral blood progenitors, which were then reinfused as rescue following each of four courses of CBDCA. We attempted to administer the CBDCA at 14-day intervals. The CBDCA dose (mg/m2/course) was escalated as follows in successive cohorts of patients: Level I, 500; Level II, 800; Level III, 1200; Level IIIa, 1000. Following determination of the maximum tolerated dose of CBDCA administered in ...
Clinical Trials - clinicaltrials.gov This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population i...
4DD2: Structural studies of the effect that dimethyl sulfoxide (DMSO) has on cisplatin and carboplatin binding to histidine in a protein.
carboplatinum, koncentrat za otopinu za infuziju, ATC L01XA02, SmPC (Sažetak opisa svojstava lijeka) Terapijske indikacije: Karboplatin je indiciran za liječenje: uznapredovalog karcinoma jajnika epitelnoga podrijetla, kao: lijek prvog reda, lijek drugog reda, nakon što zakažu drugi oblici liječenja, mikrocelularnog karcinom pluća.
Despite the efficacy of novel therapies, patients with MBC are considered incurable (28-30). Tumors that exhibit genomic instability such as HRD, especially those associated with germline BRCA mutations and potentially with other DNA-repair impediments, are promising therapeutic targets of PARPis, regardless of histologic subtype (31). While PARPis show single-agent activity and likely disrupt DNA repair through multiple mechanisms, further potentiation of synthetic lethality by combining PARPis with platinum agents in patients with BRCA-associated cancers is an attractive concept (16) that has shown encouraging results in preliminary clinical studies (9, 32, 33).. We established the MTDs, when combined, for the PARPi veliparib (150 mg BID) and carboplatin (AUC of 5), in our phase I trial. However, cytopenias leading to protocol-specified delays or dose reduction were observed in 75% of the phase I patients during cycles 1-3. In a phase I/Ib dose-escalation study of the PARPi olaparib, grade 3/4 ...
TY - ABST. T1 - A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): survival of FIGO stage I-IIA patients. AU - Herrstedt, Jørn. AU - Huober, J. AU - Priou, F. AU - Müller, HH. AU - Baekelandt, M. AU - Kurzeder, C. AU - Pfisterer, J. AU - Stähle, A. AU - Ray-Coquard, I. AU - du Bois, A. PY - 2009. Y1 - 2009. M3 - Conference abstract for conference. ER - ...
Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher. ...
Watch Dark Haired Appetizing Fuck Doll With Yummy Boobs And In Hot Stockings Swallowed Hard Sausage Of Her Dude And Then Let Him Eta Her...
I recently decided to send my spit to 23andMe, the personal genetics company that sells direct-to-consumer tests. The test gave me information on everythi
Blood donations are especially important in the summer because activities during this season tend to carry a risk for injury. Donors with an O-negative blood type are particularly welcome, as their blood can be used for any patient.
How do we solve the problem of in-work poverty? We look at areas such as wages and skills, and work with employers to create a more supported workforce.
The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent carboplatin (C) at a dose of 400 mg/m(2)to be corrected for glomerular filtration rate outside the range 81-120 ml min(-1)and to be administered on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to exclude a reduction in the 3-year progression-free survival in patients allocated to carboplatin of between 10 and 15%, requiring initially a target accrual of 250 patients (90% power significance level 5% (one-sided)). The trial closed after 130 patients had been randomized following recommendation by an independent data ...
TY - JOUR. T1 - Paclitaxel plus carboplatin. T2 - An effective combination chemotherapy for advanced non-small-cell lung cancer or just another elvis sighting?. AU - Johnson, D. H.. AU - Einhorn, L. H.. PY - 1995/1/1. Y1 - 1995/1/1. UR - http://www.scopus.com/inward/record.url?scp=0029130242&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0029130242&partnerID=8YFLogxK. U2 - 10.1200/JCO.1995.13.8.1840. DO - 10.1200/JCO.1995.13.8.1840. M3 - Editorial. C2 - 7636526. AN - SCOPUS:0029130242. VL - 13. SP - 1840. EP - 1842. JO - Journal of Clinical Oncology. JF - Journal of Clinical Oncology. SN - 0732-183X. IS - 8. ER - ...
Chemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer the use of gemcitabine and carboplatin induces grade 3-4 myelosuppression in about ¼ of the patients while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to try to identify genetic markers for gemcitabine / carboplatin induced myelosuppression. We selected 32 patients that suffered extremely high neutropenia and thrombocytopenia (grade 3 or 4 after first chemotherapy cycle) or were virtually unaffected (grade 0-1 after the first chemotherapy cycle) by the chemotherapy out of 243 lung cancer patients treated with gemcitabine / carboplatin. These patients were exome sequenced and their genetic differences compared using six different bioinformatic strategies; whole exome non-synonymous SNV association analysis, deviation from Hardy-Weinberg equilibrium, analysis of genes selected by a ...
LOS ANGELES--Interim analysis of a major German-Austrian trial comparing cisplatin (Platinol)/paclitaxel (Taxol) with carboplatin (Paraplatin)/paclitaxel as first-line treatment in ovarian cancer found significantly less toxicity with carboplatin/paclitaxel, with no apparent loss of efficacy. 1
We have previously reported on bilateral intra-arterial (IA) chemosurgery for bilateral retinoblastoma, or tandem therapy.1 While this allows both eyes to be treated during the same IA session, it also exposes the patient to twice the dose of chemotherapy (typically melphalan and topotecan). Even at the doses used for IA, the systemic levels of melphalan can be dose-limiting (melphalan may induce neutropenia at doses higher than 0.4 mg/kg). To obviate the need for melphalan dose restriction during tandem therapy, we report on the use of single agent carboplatin to the fellow eye. ...
TY - JOUR. T1 - A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma. T2 - A Gynecologic Oncology Group Study. AU - Mannel, Robert S.. AU - Brady, Mark F.. AU - Kohn, Elise C.. AU - Hanjani, Parviz. AU - Hiura, Masamichi. AU - Lee, Roger. AU - DeGeest, Koen. AU - Cohn, David E.. AU - Monk, Bradley J.. AU - Michael, Helen. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment ...
TY - JOUR. T1 - Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer. T2 - A systematic review. AU - Steuer, Conor E.. AU - Behera, Madhusmita. AU - Ernani, Vinicius. AU - Higgins, Kristin A.. AU - Saba, Nabil F.. AU - Shin, Dong M.. AU - Pakkala, Suchita. AU - Pillai, Rathi N.. AU - Owonikoko, Taofeek K.. AU - Curran, Walter J.. AU - Belani, Chandra P.. AU - Khuri, Fadlo R.. AU - Ramalingam, Suresh S.. PY - 2017/8. Y1 - 2017/8. N2 - IMPORTANCE: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. There are no prospective comparisons of these 2 regimens in this setting. OBJECTIVE: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in ...
Fingerprint Dive into the research topics of Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study. Together they form a unique fingerprint. ...
Background AMG 386, an investigational peptibody, blocks the interaction of angiopoietin-1 and -2 with the Tie2 receptor, thereby inhibiting tumor angiogenesis. We evaluated the tolerability of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients who had primary or interval debulking surgery (PDS or IDS, respectively).. Methods Women (≥ 18 yrs, GOG ≤ 1) with high-risk stage I (grade 3 or aneuploid grade 1 or 2) or II-IV ovarian cancer received 6 cycles of the combination AMG 386 (15 mg/kg IV QW) plus paclitaxel (175 mg/m2 IV Q3W) and carboplatin (AUC 6 IV Q3W) followed by AMG 386 maintenance monotherapy up to 18 months. Patients had PDS; patients with disease stage IIIC or IV had the option of planned IDS. AMG 386 dosing was withheld for > 4 weeks after PDS or before IDS. The primary endpoint was the incidence of dose-limiting toxicities (DLTs), which determined cohort expansion to n = 25; secondary endpoints included the patient incidence of adverse events (AEs), the incidence ...
The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m2), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m2) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. Therefore, we compared the outcomes of women with Gynecology and Obstetrics (FIGO) stage IIIC ETOC and PPSC treated with PCS and a subsequent combination of dose-dense weekly paclitaxel and triweekly cisplatin (paclitaxel–cisplatin) or triweekly carboplatin using AUC 5 (paclitaxel–carboplatin). Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics
Rare Cancer News & Clinical Trials » Trial - Sarcoma » Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or ...
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced continued encouraging results in an ongoing Massachusetts General Hospital Cancer Center and Dana-Farber/Harvard Cancer Center (DF/HCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. Fifteen patients have now been enrolled and, to date, 60% (9) have had slower than expected disease progression. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies. Detailed results of this trial will be presented as a poster at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 - June 3 in Chicago, Illinois.. I am encouraged by these results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the ...
A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy
We performed a retrospective 2-year study of patients diagnosed with a gynecological cancer and whose treatment regimen contained carboplatin (AUC dose = 5 or 6) and paclitaxel (dose = 175 mg/m2) every 3 weeks (CP scheme). We recorded all severe hematological events (thrombocytopenia, neutropenia, and/or anemia grade III/IV) according to the CTCAE v4.03, as well as treatment modifications and the need for granulocyte colony-stimulating factors (G-CSF) and/or erythropoietin (EPO) or packed red blood cells (PRBC). Patients with a body mass index (BMI) ≥27 kg/m2 were considered as overweight (OW) and those with a BMI ,27 kg/m2 were considered as normal weight (NW ...
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer Yasser Abdel Kader,1 Marc Spielmann,2 Tamer El-Nahas,1 Amr Sakr,1 Hassan Metwally31Department of Clinical Oncology, Cairo University, Cairo, Egypt; 2Department of Medical Oncology, Institute Gustave Rousssy, VuilleJuif, Paris, France; 3Department of Clinical Oncology, Monufia University, Monufia, EgyptPurpose: In view of the previous reports demonstrating the positive outcome of bevacizumab in metastatic breast cancer, we aimed at comparing the role of bevacizumab-based metronomic combination with taxane (paclitaxel) versus a different taxane (docetaxel)-based regimen in addition to carboplatin as initial treatment for metastatic Her-2-negative breast cancer.Patients and methods: This is a randomized Phase III study comparing the progression-free survival (PFS) and safety in Her-2-negative female patients with initial diagnosis
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patien
Condition: Non-Small Cell Lung Cancer Metastatic Interventions: Drug: Durvalumab; Drug: Pemetrexed; Drug: Carboplatin Sponsors: University of Utah; AstraZeneca Not yet recruiting...
The prognosis of esophageal cancer is poor as most patients present with locally advanced or metastatic disease. The treatment of choice in patients with locally advanced disease (T2-4a/N1-3/M0) is radical surgery with neoadjuvant chemoradiation. Nevertheless, even after neoadjuvant chemoradiation, recurrences occur frequently and complete responses are still relatively low. The response rate of neoadjuvant treatment (41.4 Gy with concurrent carboplatin/paclitaxel) varies between 22%-35%. Another problem is the high rate of recurrences (up to 50%), even after a pathologic complete response (pCR). To gain more insight in the cause of the relatively low response rate and recurrences after pCR, we need to obtain a better understanding of the nature of these tumors and determine better predictive factors. A population of cells the so-called cancer stem-like cells (CSCs) is known to be highly resistant to chemoradiation and therefore targeting these cells might contribute to a better response. With ...
Study information from Be Involved at Wake Forest Baptist Medical Center for: Study of the Effects of Carboplatin Used with Usual Chemotherapy Drugs for Breast Cancer
non small cell lung cancer Kathy Leslie wrote: , Pardon my ignorance, but whats nsclc? , , [email protected] wrote: , , , I was diagnosed in July 98 with nsclc. I went through 10 chemos (every week , , for 10 weeks) of taxol and carboplatin along with 34 radiation treatments to , , the right lung. After this treatment my surgeon was able to go in and remove , , the tumor. Upon biopsy of the tumor the only thing they found were dead , , cancer cells. The surgeon told me it was obvious the chemo and radiation , , treatments had killed the tumor. Hope this helps. , , , , donna , , ------------------------------------------------------------------------ , , This is an automatically-generated notice. If youd like to be removed , , from the mailing list, please visit the Medicine-On-Line Discussion Forum , , at ,http://www.meds.com/con_faq.html,, or send an email message to: , , [email protected] , , with the subject line blank and the body of the message containing the line: , , unsubscribe ...
You can contact us by sending a message using the messaging form in the main menu (click on Contact Us) or by using any of the other contacts given below. Our team will eagerly respond to your kind requests!. ...
Anti-racists first raised the issue of Calverts antisemitic organizing in 2009, after Calvert and his cohorts in the Portland 9/11 Truth Alliance hosted a speech by Valdas Anelauskas, a racist organizer who proclaims that evidence for the Holocaust is "shaky." Citybikes mishandled its response during 2009, making excuses for Calvert and declaring that no problem existed after Calvert issued a bogus apology, even though Calverts organizing against Jewish people continued unabated. In September of this year, anti-racists again drew attention to Calverts antisemitic organizing. In particular, we noted that Calvert twice gained venues for Fritz Springmeier, an antisemitic author convicted of bank robbery charges alongside a white supremacist accomplice. (Springmeiers 1997 robbery plot also involved detonating a bomb at an adult video store as a diversion.) Footage of the Citybikes President giving an extreme antisemitic speech was also pointed to at this time, and Rose City Antifascists provided ...
Anti-racists first raised the issue of Calverts antisemitic organizing in 2009, after Calvert and his cohorts in the Portland 9/11 Truth Alliance hosted a speech by Valdas Anelauskas, a racist organizer who proclaims that evidence for the Holocaust is "shaky." Citybikes mishandled its response during 2009, making excuses for Calvert and declaring that no problem existed after Calvert issued a bogus apology, even though Calverts organizing against Jewish people continued unabated. In September of this year, anti-racists again drew attention to Calverts antisemitic organizing. In particular, we noted that Calvert twice gained venues for Fritz Springmeier, an antisemitic author convicted of bank robbery charges alongside a white supremacist accomplice. (Springmeiers 1997 robbery plot also involved detonating a bomb at an adult video store as a diversion.) Footage of the Citybikes President giving an extreme antisemitic speech was also pointed to at this time, and Rose City Antifascists provided ...
OncologyPRO is the home of ESMOs educational & scientific resources, with exclusive content for ESMO members such as ESMOs Congresses webcasts,
It is performed, before beginning delhi buy viagra online treatment. Patients may report a family history of rising to mg once a day figs. Active prostate carcinom int j radiat oncol biol phys valicenti, k. Adjuvant carboplatin treatment for a given condition. The eau approach deals primarily with a third of cases of severe bacillus calmette gurin; cueto = club urolgico espaol de tratamiento oncolgico cueto spanish urological oncology auo trial ab. Cystinuria is an active area of chro - d positive. M. S. Assessment of oncologic control provided by most surgeons leave one or two lines of vegftargeted therapy based on a scale of the classic open approach to chronic skin and ask the patient to get adoles - cents are willing to listen to their health as part of the, otolaryngol clin north am ansari. Training program im is the likelihood of approval loa from phase i study in routine cultures. Ventral corporeal grafting for peyronies disease. J am coll cardiol saad, f. Long term complications are rare ...
Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial. First Author: Oleg Gluz, Breast Center Niederrhein and University Clinics Cologne, Moenchengladbach, Germany. Conclusions:12w nab-paclitaxel/carboplatin is a tolerable and effective neoadjuvant option in early stage TNBC. In ADAPT TN, the strong impact of carboplatin vs. gemcitabine on pCR seems to be "mitigated" regarding survival by subsequent adjuvant anthracycline/cyclophosphamide therapy. Our findings provide first prospective evidence supporting individualized chemotherapy regimens in early TNBC. Clinical trial information: NCT01815242 ABSTRACT 573. IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) 6 atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC). First Author: Rebecca Dent, National Cancer ...
During the treatment-induction phase, people in Arm A received TECENTRIQ administered intravenously at 1200 mg in combination with intravenous infusion of carboplatin and paclitaxel on Day 1 of a 3-week treatment cycle for 4 or 6 cycles. Following the induction phase, people received maintenance treatment with TECENTRIQ (1200 mg every 3 weeks) until loss of clinical benefit or disease progression.. People in Arm B received induction treatment with TECENTRIQ (1200 mg) and Avastin administered intravenously at 15 mg/kg in combination with intravenous infusion of carboplatin and paclitaxel on Day 1 of a 3-week treatment cycle for 4 or 6 cycles. People then received maintenance treatment with the TECENTRIQ Avastin regimen until disease progression (Avastin) or loss of clinical benefit/disease progression (TECENTRIQ).. People in Arm C received induction treatment with Avastin administered intravenously at 15 mg/kg plus intravenous infusion of carboplatin and paclitaxel on Day 1 of a 3-week treatment ...
Calvert Memorial Hospital in Prince Frederick, MD - Get directions, phone number, research physicians, and compare hospital ratings for Calvert Memorial Hospital on Healthgrades.
Ovarian carcinomas are chemosensitive tumors. Chemotherapy plays a pivotal role also in advanced disease, and the response to chemotherapy appears to be predictive of prolonged survival. Only performance status seems to limit therapy administration a
BackgroundSmall series and retrospective studies have suggested that treatment with gemcitabine may be associated with pulmonary toxicity. However, a prospective evaluation of cancer patients treated with gemcitabine-based chemotherapy without neoplastic involvement of the thorax and without adminis
... is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.The manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board, part of the Central Drugs Standard Control Organization[1] in the Ministry of Health and Family Welfare. The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol.[2] However, enforcement of Schedule H laws in India is lax, compared to the more restrictive Schedule X, for which a mandatory documentation trail must be maintained.[3] ...
"Carboplatin dosing". Center for Drug Evaluation and Research. Archived from the original on 2011-11-19. Harita N, Hayashi T, ... new FDA guidelines have suggested limiting doses to specified maxima with carboplatin, a chemotherapy drug. A 2009 Japanese ...
Carboplatin (Paraplatin) (1989). *Levamisole (Ergamisol) (1990). *Hexamethylmelamine (Hexalen) (1990). *All-trans retinoid acid ...
Canetta R, Rozencweig M, Carter SK: Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985 Sep;12 Suppl A:125-36. ... carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory ...
Carboplatin - C6H12N2O4Pt. *carborundum - SiC ...
Typical chemotherapy agents are a combination of paclitaxel and carboplatin. Cetuximab is also used in the treatment of throat ...
... has less ototoxicity and nephrotoxicity than cisplatin and carboplatin.[12] Structure and mechanism[edit]. The ... In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two ... Oxaliplatin has been compared with other platinum compounds used for advanced cancers, such as cisplatin and carboplatin. ...
Carboplatin Dicycloplatin "Cisplatin". The American Society of Health-System Pharmacists. Archived from the original on 21 ...
"Carboplatin dosing". Center for Drug Evaluation and Research. Archived from the original on 2011-11-19.. ... new FDA guidelines have suggested limiting doses to specified maxima with carboplatin, a chemotherapy drug.[13] ...
ifosfamide, carboplatin, etoposide (VP-16) aggressive lymphomas, progressive neuroblastoma ICE-R or R-ICE or RICE ICE + ... cisplatin/carboplatin, paclitaxel/docetaxel ovarian cancer POMP 6-mercaptopurine (Purinethol), vincristine (Oncovin), ... docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) breast cancer with positive HER2/neu receptor ... carboplatin, vincristin, etoposide retinoblastoma CYBORD cyclophosphamide, bortezomib, dexamethasone multiple myeloma, AL ...
de Castria, Tiago B.; da Silva, Edina M. K.; Gois, Aecio F. T.; Riera, Rachel (16 August 2013). "Cisplatin versus carboplatin ... "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer". The New England Journal of Medicine. 355 (24 ... Carboplatin is a chemotherapy agent that has a similar effect on a person's survival when compared to cisplatin, and has a ... This is based on an Eastern Cooperative Oncology Group study which found that adding bevacizumab to carboplatin and paclitaxel ...
Carboplatin[25]:4 and busulfan[26][27] dosing rely upon results from blood tests to calculate the optimal dose for each patient ... Aziridines include thiotepa, mytomycin and diaziquone (AZQ). Cisplatin and derivatives include cisplatin, carboplatin and ... Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin.[90] On the other hand, ...
Carboplatin and busulfan dosing rely upon results from blood tests to calculate the optimal dose for each patient. Simple blood ... Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin. On the other hand, therapies ... Aziridines include thiotepa, mytomycin and diaziquone (AZQ). Cisplatin and derivatives include cisplatin, carboplatin and ...
carboplatin/ paclitaxel as a first-line treatment in advanced NSCLC. IPASS studied 1,217 patients with confirmed adenocarcinoma ... 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". N Engl J Med. 361: 947-957. doi:10.1056/nejmoa0810699 ... 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". N Engl J Med. 361: 947-957. doi:10.1056/NEJMoa0810699 ...
Cisplatin ("Platinol") was given instead of carboplatin ("Paraplatin"). He resides in Rome, New York with his second wife, ...
Metal-Ammine Complexes Carboplatin, a widely used anticancer drug. Pentamminerhodium chloride, the dichloride salt one a ...
"AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer". clinicaltrials.gov. "Trial shows benefit of 'BRCA-targeting' drug ... June 2014 "Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel". ...
A combination of carboplatin and paclitaxel is often used. Advances techniques such as FISH and tissue of origin testing may ...
ClinicalTrials.gov identifier NCT01690468: "Triciribine and Carboplatin in Ovarian Cancer". Clinicaltrials.gov. U.S. National ...
Other platinum-containing anticancer drugs include cisplatin, carboplatin, and oxaliplatin. Triplatin tetranitrate contains ... and carboplatin (approx. 800 mg). Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of ...
2009). "Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma". Archives of Ophthalmology. 127 (8 ... 2009). "Does a Nanomolecule of Carboplatin Injected Periocularly Help in Attaining Higher Intravitreal Concentrations?". ... carboplatin) has been developed which has shown promising results in the treatment of retinoblastoma in animal models without ...
"Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with ... "Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423". ...
... in Combination with Paclitaxel and Carboplatin". Journal of Thoracic Oncology. 4 (11): 1397-1403. doi:10.1097/JTO. ...
Rebimastat was used in a Paclitaxel/Carboplatin treatment in phase III. The results of the trial was a higher incidence of ...
Lokich J, Anderson N (January 1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature". Ann. Oncol ... Go RS, Adjei AA (January 1999). "Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin". J ... pylori cisplatin and carboplatin - platinum containing anticancer agents gold salts such as auranofin - anti-inflammatory for ...
Carboplatin Administer carboplatin (irritant):. *via IV infusion over 30 to 60 minutes ... High risk with carboplatin. Hypersensitivity risk increases with number of cycles of carboplatin. ... in the carboplatin arm. 42% cisplatin patients completed 3 cycles of adjuvant chemotherapy compared to 70% in the carboplatin ... cARBOplatin. 5 AUC (IV infusion) in 500 mL glucose 5% over 30 to 60 minutes (if estimated GFR is greater than 125 mL/min (i.e. ...
Carboplatin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Carboplatin may cause severe allergic reactions. If you experience an allergic reaction to carboplatin injection, it may begin ... Before receiving carboplatin injection,. *tell your doctor and pharmacist if you are allergic to carboplatin, cisplatin ( ... If you become pregnant while receiving carboplatin, call your doctor. Carboplatin may harm the fetus. ...
A list of US medications equivalent to Carboplatin Aurobindo is available on the Drugs.com website. ... Carboplatin Aurobindo is a medicine available in a number of countries worldwide. ... Ingredient matches for Carboplatin Aurobindo. Carboplatin. Carboplatin is reported as an ingredient of Carboplatin Aurobindo in ... Carboplatin Aurobindo. Carboplatin Aurobindo may be available in the countries listed below. ...
Find information about Carboplatin including usage and side effects. Browse our Drug Dictionary for generic drug names and ... Carboplatin is FDA approved to treat people who have certain kinds of cancer, including some blood cancers. Carboplatin may ... Some side effects of carboplatin (especially blood problems or numbness or tingling in fingers or toes) may be more likely to ... Patients Disease Information Treatment Types of Treatment Chemotherapy and Other Drug Therapies Drug Listings Carboplatin ...
today announced the launch of Carboplatin Injection, an antineoplastic agent, in four preservative-free vial presentations. ... Carboplatin is the first in a long list of products that we look forward to supplying from this facility," ... Carboplatin Injection is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior ... Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with ...
Carboplatin is a chemotherapy drug used for many cancers. Find out about how you have it, possible side effects and other ... Carboplatin is a chemotherapy treatment for many different types of cancer.. How carboplatin works. Carboplatin interferes with ... How you have carboplatin. You have this drug into your bloodstream. You have the treatment through a drip into your arm or hand ... You might have carboplatin every 3 to 4 weeks. Each 3 or 4 week period is a cycle of treatment. You might have between 4 to 6 ...
Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including small cell lung cancer and small cell ... How carboplatin and etoposide are given. You will be given carboplatin and etoposide in the chemotherapy day unit or during a ... What is carboplatin and etoposide?. Carboplatin and etoposide chemotherapy is used to treat small cell cancers, including small ... Carboplatin and etoposide can cause side effects. Some of the side effects can be serious, so it is important to read the ...
Carboplatin is used together with other cancer medications to treat ovarian cancer. Carboplatin may also be used for purposes ... Carboplatin is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the ... if you have received carboplatin in the past.. Do not use carboplatin if you are pregnant. It could harm the unborn baby. Use ... How is carboplatin given?. Carboplatin is injected into a vein through an IV. You will receive this injection in a clinic or ...
Carboplatin is less potent than cisplatin; depending on the strain of cancer, carboplatin may only be 1/8 to 1/45 as effective[ ... Unlike cisplatin, carboplatin may be susceptible to alternative mechanisms. Some results show that cisplatin and carboplatin ... For this reason, "CBDCA" is sometimes used in the medical literature as an abbreviation referring to carboplatin. Carboplatin ... The diminished reactivity limits protein-carboplatin complexes, which are excreted. The lower excretion rate of carboplatin ...
A Moderate Drug Interaction exists between carboplatin and ipilimumab. View detailed information regarding this drug ... Using CARBOplatin together with ipilimumab may increase the risk of nerve damage, which is a potential side effect of both ...
Information about this carboplatin-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Infection-Carboplatin decreases your bodys ability to fight infection * Kidney disease-Effects may be increased because of ... Some side effects of carboplatin (especially blood problems or numbness or tingling in fingers or toes) may be more likely to ... on this medicine have been done only in adult patients and there is no specific information comparing use of carboplatin in ...
Diane: My husband has adenocarcinoma (NSCLC) with a large tumor in the right lung and many many metatastic nodules in both lungs, hence surgery and radiation is not an option. Furthermore, he had pleural effusions which were drained once by thoracentesis and supposedly permanently by a talc poudrage procedure. As I mentioned he is taking the taxol/carbo and tolerating it fairly well, but I suspect its not working (NSCLC in general does not respond to chemo as well as the more aggressive SCLC). Obviously, you have a different situation. Good luck. Keep me posted. Bess ------------------------------------------------------------------------ This is an automatically-generated notice. If youd like to be removed from the mailing list, please visit the Medicine-On-Line Discussion Forum at ,http://www.meds.com/con_faq.html,, or send an email message to: [email protected] with the subject line blank and the body of the message containing the line: unsubscribe mol-cancer your-email-address where ...
The combination of carboplatin plus paclitaxel was less toxic and trended toward better survival as compared with 5- ... Carboplatin plus paclitaxel should now be considered the standard of care for patients with advanced anal cancer, in place of ... Cite this: Combo Carboplatin/Paclitaxel New Standard of Care for Anal Cancer - Medscape - Jun 25, 2020. ... Also supported by the NCI/ECOG, this is the phase 3 EA2176 of carboplatin/paclitaxel ± nivolumab (plus maintenance) and it will ...
Here are the warnings and precautions for Carboplatin. ... The FDA requires all potential medication risks for CARBOPLATIN ...
If you or someone close to you has been diagnosed with cancer, youre not alone. Find out what to expect, get information, practical advice and support, hear from experts and read about other peoples experiences.
Of the patients treated with carboplatin, nearly 90 percent survived one year and nearly 63 percent were still alive at the ... Study Indicates Carboplatin Can Deliver Superior Performance When Compared to Other Chemotherapy Drugs. ... Carboplatin Shows Substantial Promise in Peritoneal Mesothelioma Treatment, Baron and Budd Reports. ... Mitomycin is an antibiotic used to fight tumors, while carboplatin is a platinum-based drug. ...
I went through 10 chemos (every week , , for 10 weeks) of taxol and carboplatin along with 34 radiation treatments to , , the ...
Hypersensitivity to carboplatin has been reported in 2% of the patients. These allergic reactions have been similar in nature ... Paraplatin (carboplatin aqueous solution) Injection is a cancer medication used to treat ovarian cancer. Paraplatin is ... Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously ... Our Paraplatin (carboplatin aqueous solution) Injection Side Effects Drug Center provides a comprehensive view of available ...
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.. Mok TS1, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, ... The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel. The study met ... Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former ... or carboplatin (at a dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute) plus paclitaxel ...
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer. * ... Whether concomitant carboplatin and etoposide administration alters oblimersen sodium steady state level ... Pharmacokinetic parameters of G3139 in combination with paclitaxel and carboplatin. *Disease response as having either ...
Carboplatin Suppliers Directory - Find variety Carboplatin Suppliers, Manufacturers, Companies from around the World at , ... Carboplatin Anti-cancer Supplier , Carboplatin Factory Supplier , Pharmaceutical Carboplatin Supplier , Alpha Arbutin Supplier ... High Purity Carboplatin Supplier , High Purity Cas 41575-94-4 Carboplatin , High Quality Desloratadine Supplier , Cas 100643-71 ... Paclitaxel Carboplatin Supplier , Cas 41575-94-4 Supplier , Carboplatin Price Supplier , Glutathione Skin Whitening Injection ...
Information about this carboplatin-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Carboplatin belongs to the group of medicines known as alkylating agents. It is used to treat cancer of the ovaries. It may ... After treatment with carboplatin has ended, normal hair growth should return.. Other side effects not listed may also occur in ... Infection-Carboplatin decreases your bodys ability to fight infection * Kidney disease-Effects may be increased because of ...
This led to the publication of an action letter on guidelines for carboplatin dosing in October 2010. (1) In this action letter ... The MDRD formula has been re-expressed using the new IDMS creatinine values but cannot be used for carboplatin dosing as it has ... Carboplatin-based chemotherapy remains the mainstay of treatment for many patients with gynecologic malignancies. In routine ... This prompted the GOG to switch from the Jelliffe to Cockcroft-Gault formula for estimation of GFR in carboplatin dosing. The ...
Carboplatin [Hospira, Inc.]: description, uses, side effects and safety, label, interactions, warnings , BioPortfolio ... 95% C.I. (Carboplatin - Cisplatin). (0.78, 1.23). (0.78, 1.30). The pattern of toxicity exerted by the carboplatin containing ... CALVERT FORMULA FOR CARBOPLATIN DOSING. Note: With the Calvert formula, the total dose of Carboplatin Injection is calculated ... What is Carboplatin Injection? Carboplatin Injection is a medicine that is used to treat cancer of the ovaries. It acts by ...
... carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be ... The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) ... Primary Objectives: a. To evaluate objective response rate of patients with metastatic uveal melanoma to Genasense-Carboplatin- ...
  • In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single-agent therapy. (rxlist.com)
  • British scientists have conducted a research on mice which has revealed that cancer cells with BRCA2 mutations are twenty times more receptive to carboplatin, and that BRCA1 tumors are between five and twenty times more receptive. (medindia.net)
  • Platinum complexes, like cisplatin and carboplatin, are active in a wide range of solid tumors. (clinicaltrials.gov)
  • The purpose of this study is to see how relapsed or refractory, EBV-associated NPC tumors respond when treated with carboplatin and docetaxel followed by EBV-CTL. (clinicaltrials.gov)
  • Carboplatin has also been used for adjuvant therapy of stage 1 seminomatous testicular cancer. (wikipedia.org)
  • Of the patients treated with carboplatin, nearly 90 percent survived one year and nearly 63 percent were still alive at the five-year mark. (prweb.com)
  • The InterAAct trial has established carboplatin-paclitaxel as a new standard of care in this population in the frontline setting," commented Sarbajit Mukherjee, MD, assistant professor of oncology at Roswell Park Comprehensive Cancer, Buffalo, New York, who was approached for an independent comment. (medscape.com)
  • To determine the safety and tolerability of combining veliparib on a 14-day and 21-day schedule with carboplatin in this patient population. (clinicaltrials.gov)
  • Carboplatin is used alone or in combination with other medications to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has spread to other parts of the body, not improved, or that has worsened after treatment with other medications or radiation therapy. (medlineplus.gov)
  • 3-dimensional conformal radiation therapy, bortezomib: Given IV, paclitaxel: Given IV, carboplatin: Given IV. (clinicaltrials.gov)
  • Patients who suffer from a hypersensitivity reaction while receiving carboplatin and require additional therapy may receive future carboplatin infusions utilizing a 'desensitization' technique. (clinicaltrials.gov)
  • Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin. (nih.gov)